This is a test discussion starter

0 comments

0

0 comments

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited.

UK | February 2021 | 105991

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.UK/yellowcard (UK).

Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com

To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.

Technical Support

Prescribing information can be found at the links below:

ADAKVEO®▼ (crizanlizumab) | EXJADE®▼ (deferasirox) | JAKAVI® (ruxolitinib) | KYMRIAH®▼ (tisagenlecleucel)

REVOLADE® (eltrombopag) | RYDAPT®▼(midostaurin) | TASIGNA® (nilotinib) / GLIVEC®▼ (imatinib)